Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 2 / 3 Trials for Cabazitaxel (DB06772)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03295565Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With DocetaxelTreatment